当前位置： SCI文献检索 > CARDIOVASCULAR RESEARCH期刊下所有文献 > Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control.

Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control.

Abstract：

AIMS:Arrhythmias and sudden cardiac death (SCD) occur commonly in patients with heart failure. We found T-box 5 (TBX5) dysregulated in ventricular myocardium from heart failure patients and thus we hypothesized that TBX5 reduction contributes to arrhythmia development in these patients. To understand the underlying mechanisms, we aimed to reveal the ventricular TBX5-dependent transcriptional network and further test the therapeutic potential of TBX5 level normalization in mice with documented arrhythmias. METHODS AND RESULTS:We used a mouse model of TBX5 conditional deletion in ventricular cardiomyocytes. Ventricular (v) TBX5 loss in mice resulted in mild cardiac dysfunction and arrhythmias and was associated with a high mortality rate (60%) due to SCD. Upon angiotensin stimulation, vTbx5KO mice showed exacerbated cardiac remodelling and dysfunction suggesting a cardioprotective role of TBX5. RNA sequencing of a ventricular specific TBX5KO mouse and TBX5 chromatin immunoprecipitation were used to dissect TBX5 transcriptional network in cardiac ventricular tissue. Overall, we identified 47 transcripts expressed under the control of TBX5, which may have contributed to the fatal arrhythmias in vTbx5KO mice. These included transcripts encoding for proteins implicated in cardiac conduction and contraction (Gja1, Kcnj5, Kcng2, Cacna1g, Chrm2), in cytoskeleton organization (Fstl4, Pdlim4, Emilin2, Cmya5), and cardiac protection upon stress (Fhl2, Gpr22, Fgf16). Interestingly, after TBX5 loss and arrhythmia development in vTbx5KO mice, TBX5 protein level normalization by systemic adeno-associated-virus (AAV) 9 application, re-established TBX5-dependent transcriptome. Consequently, cardiac dysfunction was ameliorated and the propensity of arrhythmia occurrence was reduced. CONCLUSIONS:This study uncovers a novel cardioprotective role of TBX5 in the adult heart and provides preclinical evidence for the therapeutic value of TBX5 protein normalization in the control of arrhythmia. TRANSLATIONAL PERSPECTIVE:Cardiovascular disease (CVD) is the number one cause of death worldwide (WHO factsheets 09/2016). Although more than 60% of CVD-related deaths are due to out-of-hospital sudden cardiac death (SCD), we have little insight in the mechanisms underlying SCD pathophysiology. Our data show a link between TBX5 dysregulation and arrhythmia occurrence in patients. To test the therapeutic potential of TBX5, we normalized TBX5 levels in a mouse model with TBX5 dysregulation, which developed arrhythmias and SCD. TBX5 normalization re-established TBX5 target gene expression and more importantly, rescued the arrhythmia phenotype. Altogether, we provide proof-of-concept for the therapeutic potential of TBX5 expression restoration against arrhythmia and SCD.

journal_name

Cardiovasc Res

journal_title

Cardiovascular research

authors

Rathjens FS,Blenkle A,Iyer LM,Renger A,Syeda F,Noack C,Jungmann A,Dewenter M,Toischer K,El-Armouche A,Müller OJ,Fabritz L,Zimmermann WH,Zelarayan LC,Zafeiriou MP

doi

10.1093/cvr/cvaa239

subject

Has Abstract

pub_date

2020-08-10 00:00:00

eissn

0008-6363

issn

1755-3245

pii

5890468

pub_type

杂志文章

在线工具

Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia control.